https://www.selleckchem.com/pr....oducts/phorbol-12-my
001) and other in-hospital adverse events were significantly more frequent in patients with than without SB, whereas the 30-day readmission rate was similar (13.2 vs. 15.1%; p = .572). After adjustment for patient and hospital characteristics, SB was significantly associated with higher in-hospital mortality (odds ratio = 6.67, 95% confidence interval = 4.35, 10.23, p .001). This study suggests that although the incidence of SB after TMVr is decreasing, SB is required more frequently in lower-volume hospital